Regulatory Blog

Appropriate eligibility criteria are essential for protecting trial participants while ensuring that clinical trial populations are representative of patients who are expected to receive the investigational therapy in clinical practice. Overly restrictive eligibility criteria may unnecessarily exclude patients, delay trial enrollment, and limit the applicability of study results. The three FDA guidances—Cancer Clinical Trial Eligibility Criteria: Laboratory Values, Cancer Cli

Biosimilar medicines have become an integral part of modern healthcare by expanding patient access to biological therapies while maintaining high standards of quality, safety, and efficacy. As scientific knowledge, analytical technologies, and regulatory frameworks continue to evolve, regulatory guidance must also adapt to reflect these advancements. The Concept Paper on Revision of the Guideline on Similar Biological Medicinal Products sets out the European Medicines Agency'

Clinical investigations are an essential part of demonstrating the safety and performance of medical devices before they are placed on the market. Organizations conducting investigations in Great Britain must ensure that studies are appropriately planned, approved, and supported with complete regulatory documentation. The guidance documents Clinical Investigations in Great Britain, Approving Clinical Investigations, and Compiling a Submission outline the regulatory framework,

Artificial Intelligence (AI) is increasingly being explored across evidence generation, analysis, and reporting, offering opportunities to improve the efficiency of processes supporting health technology assessment. However, when AI is used to prepare evidence for regulatory and assessment purposes, its potential benefits must be balanced against risks to completeness, methodological quality, scientific rigour, and reliability. To address these considerations, the Member Stat

Efficient regulatory submissions depend not only on preparing high-quality dossiers but also on using the correct submission systems and selecting the appropriate regulatory pathway. For companies seeking to submit medicines applications, clinical trial documentation, or safety reports in the UK, understanding the Medicines and Healthcare products Regulatory Agency (MHRA) submission infrastructure is essential. The MHRA provides guidance covering two important areas: Register

The UK clinical trials regulatory framework has undergone significant changes following amendments to the Medicines for Human Use (Clinical Trials) Regulations. These changes introduce updated requirements across clinical trial conduct, safety reporting, transparency, Good Clinical Practice (GCP), investigational medicinal products, and regulatory oversight. To support sponsors and investigators, the Medicines and Healthcare products Regulatory Agency (MHRA) has published upd

Ending a clinical trial is an important regulatory milestone that requires sponsors to meet specific notification, transparency, and reporting obligations. Properly closing a trial ensures that regulatory authorities are informed, trial results are made publicly available, and participants have access to understandable information about the research in which they participated. The Medicines and Healthcare products Regulatory Agency (MHRA) has published the guidance Clinical T

Before approving a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), the U.S. Food and Drug Administration (FDA) must ensure that the manufacturing facilities are capable of consistently producing medicines that meet Current Good Manufacturing Practice (CGMP) requirements. Preapproval Inspections (PAIs) are conducted to evaluate manufacturing readiness, verify the accuracy of Chemistry, Manufacturing and Controls (CMC) information, and confirm that facili

Innovation is transforming medicinal product development through the introduction of novel methodologies such as biomarkers, digital health technologies, artificial intelligence (AI), modelling and simulation, real-world data, patient registries, and advanced non-clinical testing methods. These approaches have the potential to improve evidence generation, streamline drug development, and support more informed regulatory decision-making. However, before they can be widely adop

Timely access to innovative medicines and biosimilars is an important objective for regulatory authorities worldwide. Collaborative assessment models enable regulators to share scientific expertise, reduce duplication of effort, and accelerate the availability of high-quality, safe, and effective medicines for patients. International work-sharing initiatives also promote regulatory convergence while maintaining robust scientific evaluation standards. The Medicines and Healthc

Access to accurate and up-to-date medicinal product information is essential for the safe prescribing, dispensing, and use of medicines. Healthcare professionals rely on authorised product information to make informed clinical decisions, while patients depend on clear instructions to use medicines safely and effectively. Providing easy access to approved regulatory information also promotes transparency throughout a medicine's lifecycle. The Medicines and Healthcare products

Pharmacovigilance plays a critical role in protecting public health by enabling the timely identification, assessment, and management of medicine safety concerns. Accurate reporting of adverse drug reactions (ADRs) and Adverse Events Following Immunisation (AEFIs) allows regulatory authorities to continuously monitor the benefit-risk profile of authorised medicines and implement appropriate regulatory actions when necessary. To strengthen electronic pharmacovigilance reportin

Artificial Intelligence (AI) is rapidly transforming drug development by enabling more efficient data analysis, predictive modelling, and evidence-based decision-making. Early-phase clinical trials, particularly Phase 1 studies, represent one of the most challenging stages of drug development due to uncertainties surrounding dose selection, patient recruitment, safety monitoring, and progression decisions. Improving the efficiency of these trials has the potential to accelera

Marketing Authorisations (MAs) require updates throughout a medicine's lifecycle to reflect changes in manufacturing, quality, safety, efficacy, product information, or administrative details. To ensure that these changes are appropriately assessed and approved while maintaining product quality and patient safety, the Medicines and Healthcare products Regulatory Agency (MHRA) provides detailed guidance on applying for variations to UK Marketing Authorisations. The MHRA guidan

Medicines labelling and packaging are fundamental to the safe and effective use of medicines. Clear packaging enables patients, carers, pharmacists, and healthcare professionals to correctly identify medicines, understand essential safety information, and minimise the risk of medication errors. Poor label design, confusing layouts, or lookalike packaging can contribute to dispensing mistakes and inappropriate medicine use. To promote consistent and patient-focused packaging,

Medicines packaging, labelling, and Patient Information Leaflets (PILs) are essential components of medicine safety and regulatory compliance. They provide healthcare professionals and patients with critical information regarding the safe use, storage, administration, and identification of medicinal products. Throughout a medicine's lifecycle, these materials must remain accurate, up to date, and consistent with the approved product information to support patient safety and r

Next-generation sequencing (NGS) has become an essential tool in antiviral drug development, enabling detailed analysis of viral genetic changes and the identification of resistance-associated variants. Compared with traditional sequencing methods, NGS generates extensive sequence data that provides a deeper understanding of viral populations throughout clinical development. To promote consistent and high-quality regulatory submissions, the U.S. Food and Drug Administration (

Maintaining the safety of the blood supply is a critical public health priority, particularly during outbreaks of emerging infectious diseases. Ebola disease, caused by viruses of the Orthoebolavirus genus, is associated with severe illness and can be transmitted through direct contact with infected body fluids. Although transfusion-transmitted Ebola disease has not been widely documented, the potential risk of transmission through blood and blood components requires appropri

As regulatory systems become increasingly digital, standardized medicinal product data has become essential for improving regulatory efficiency and ensuring consistent information across the European medicines network. To support this transition, the European Medicines Agency (EMA) published the guidance Product Management Services (PMS) – Implementation of ISO Standards for the Identification of Medicinal Products (IDMP) in Europe – Chapter 3: Process for the Electronic Subm

Environmental sustainability is becoming an essential consideration in pharmaceutical manufacturing as production activities consume significant amounts of energy, water, raw materials, and solvents while generating emissions, effluents, and waste. These activities can affect ecosystems, contribute to climate change, and influence long-term public health. To help manufacturers integrate sustainable practices into pharmaceutical operations, the World Health Organization (WHO)